molecular
chaperon
heatshock
protein
involv
stabil
conform
matur
mani
signal
protein
deregul
cancer
inhibit
result
proteasom
degrad
client
protein
lead
potent
antitumor
activ
inhibitor
present
clinic
trial
recent
work
identifi
role
multipl
signal
transduct
pathway
reveal
molecular
mechan
tumor
select
inhibitor
result
activ
highaffin
conform
tumor
review
discuss
recent
advanc
understand
tumor
treatment
diagnosi
cancer
addit
role
nononcolog
diseas
also
discuss
ubiquit
molecular
chaperon
protein
involv
fold
activ
assembl
mani
protein
includ
key
mediat
signal
transduct
cellcycl
control
transcript
regul
client
protein
includ
transmembran
tyrosin
kinas
epiderm
growth
factor
receptor
egfr
met
insulinlik
growth
receptor
metast
signal
protein
akt
ikk
mutat
signal
protein
kit
vsrc
chimer
signal
protein
npm
alk
bcrabl
steroid
receptor
androgen
estrogen
progesteron
receptor
cellcycl
regul
regul
cochaperon
protein
particip
order
seri
dynam
multiprotein
complex
link
conform
coupl
atpas
cycl
client
protein
bind
intermedi
complex
contain
cochaperon
protein
hip
hop
upon
atp
bind
hydrolysi
form
matur
complex
contain
immunophilin
ip
catalyz
conform
matur
client
protein
figur
natur
occur
ansamycin
antibiot
geldanamycin
bind
conserv
bind
pocket
ntermin
atpbind
domain
inhibit
atp
bind
atpdepend
chaperon
activ
direct
proteasom
degrad
client
protein
geldanamycin
display
potent
antitumor
activ
vitro
hepatotox
clinic
use
less
toxic
geldanamycin
deriv
also
bind
exert
potent
antitumor
activ
preclin
model
current
clinic
trial
modul
preferenti
target
tumor
cell
even
though
abundantli
express
normal
tumor
cell
unknown
furthermor
unclear
bind
recombinantli
isol
protein
micromolar
affin
commonli
kill
tumor
cell
line
nanomolar
concentr
recent
data
reveal
therapeut
select
inhibitor
result
presenc
highaffin
activ
form
tumor
multichaperon
complex
high
atpas
activ
wherea
normal
tissu
inact
uncomplex
form
low
affin
review
discuss
role
multipl
signal
transduct
pathway
diagnost
therapeut
implic
molecular
mechan
tumor
select
inhibitor
structur
implic
activ
format
multichaperon
complex
also
discuss
potenti
use
drug
nononcolog
diseas
inhibit
affect
multipl
signal
pathway
influenc
activ
stabil
mani
client
protein
function
key
regul
cellular
growth
differenti
apoptot
pathway
known
client
regul
multipl
signal
transduct
pathway
persist
activ
human
cancer
inactiv
erk
phosphatidyl
kinas
akt
pathway
inhibitor
caus
downregul
cyclin
function
inactiv
import
cell
cycl
transit
figur
growth
factor
receptor
sensit
degrad
includ
receptor
egf
plateletderiv
growth
factor
pdgf
inhibitor
inactiv
multipl
kinas
akt
furthermor
inactiv
akt
inhibitor
lead
reduc
bad
death
promot
phosphoryl
decreas
activ
antiapoptot
protein
bclx
therebi
induc
apoptosi
cytochrom
c
releas
inhibitor
also
inactiv
steroid
receptor
androgen
receptor
estrogen
receptor
bound
cognat
ligand
transloc
nucleu
act
transcript
factor
therefor
inhibitor
simultan
destabil
mani
oncoprotein
multipl
signal
pathway
suggest
inhibit
could
particularli
benefici
attack
latestag
cancer
cell
easili
circumv
blockad
singl
target
pathway
wide
array
client
protein
inhibitor
use
target
divers
cancer
client
protein
necessari
cancer
prolifer
surviv
progress
particular
one
client
protein
sensit
inhibitor
promis
preclin
data
breastand
prostatecanc
model
suggest
could
use
treat
tumor
discoveri
bcrabl
fusion
protein
sole
caus
factor
chronic
myelogen
leukemia
cml
client
led
studi
show
geldanamycin
induc
apoptosi
cmlderiv
cell
line
furthermor
cml
cell
becom
resist
bcrabl
inhibitor
gleevec
remain
sensit
suggest
drug
could
benefici
gleevecresist
patient
addit
data
indic
leukemia
lymphoma
depend
chimer
mutat
protein
npm
alk
itd
ckit
target
drug
therefor
inhibitor
could
potenti
affect
broad
rang
cancer
variou
ongo
clinic
trial
use
aim
determin
whether
true
highaffin
conform
tumor
confer
drug
select
inhibitor
drug
select
kill
cancer
cell
even
though
wide
express
normal
tissu
recent
studi
report
tumor
cell
maintain
activ
conform
format
multichaperon
complex
increas
atpas
activ
greater
bind
affin
compar
uncomplex
latent
form
present
normal
cell
interestingli
tumor
cell
overexpress
clientprotein
exhibit
highest
bind
affin
accord
recent
report
overexpress
tumor
cell
confer
increas
sensit
geldanamycin
increas
bind
affin
tumor
also
explain
remark
abil
drug
accumul
select
tumor
compar
normal
tissu
vivo
furthermor
result
suggest
usag
indic
bindingaffin
true
predictor
depend
tumor
cell
report
level
elev
mani
cancer
tissu
probabl
activ
close
link
cancer
progress
least
earli
stage
malign
progress
proce
complet
usag
tumor
within
cell
might
provid
select
pressur
lead
upregul
observ
mani
advanc
tumor
model
malign
progress
propos
tumor
cell
gradual
accumul
mutant
overexpress
signal
protein
becom
engag
activ
chaperon
stabil
oncoprotein
adopt
highaffin
form
induc
bound
cochaperon
protein
figur
contrast
normal
cell
appear
larg
unus
remain
uncomplex
form
lowaffin
bind
inhibitor
model
would
also
predict
base
current
knowledg
proteotox
stress
normal
cell
would
convert
inact
complex
higher
bind
affin
transcript
regul
heatshock
transcript
factor
thought
regul
sequestr
inact
state
cytosol
condit
proteotox
stress
eg
heat
recruit
refold
partial
denatur
protein
liber
sequest
complex
enabl
trimer
transloc
nucleu
transactiv
heatshock
gene
assum
stressinduc
chaperon
activ
atpdepend
transit
accompani
sharp
increas
usag
commensur
increas
affin
cellular
pool
inhibitor
similarli
interest
specul
whether
de
novoinduc
high
low
affin
drug
activ
agent
bind
ntermin
atp
site
also
caus
dissoci
complex
robust
heatshock
respons
possibl
time
window
cytotox
activ
inhibitor
could
limit
develop
druginduc
heatshock
respons
induc
uncomplex
low
affin
compet
poorli
preexist
highaffin
complex
contain
client
protein
bind
altern
repopul
cytosol
activ
highaffin
complex
might
expect
dampen
ongo
antitumor
respons
fact
sever
cochaperon
gene
target
coordin
induc
heatshock
respons
indic
latter
possibl
like
crystal
structur
ntermin
domain
bound
either
geldanamycin
radicicol
atp
adp
figur
solv
key
amino
acid
within
ntermin
bind
pocket
form
crucial
interact
compound
import
note
howev
structur
inform
base
free
uncomplex
activ
form
compris
multichaperon
protein
complex
impart
structur
chang
atpbind
site
evidenc
dramat
increas
bind
activ
inhibitor
precis
bind
configur
inhibitor
activ
form
remain
determin
base
upon
crystal
structur
atp
bound
analogu
figur
exhibit
cshape
compact
conform
synthes
crystal
structur
recombin
solv
smallmolecul
compound
also
exhibit
mani
biolog
properti
classic
inhibitor
remain
determin
whether
compound
also
bind
complex
higher
affin
geldanamycin
deriv
differ
bind
activ
complex
versu
free
might
explain
conform
differ
geldanamycin
ligand
unligand
form
similar
atp
geldanamycin
deriv
adopt
compact
cshape
conform
bound
unlik
extend
planar
structur
unbound
geldanamycin
flexibl
conform
probabl
enabl
geldanamycin
adopt
precis
conform
necessari
bind
complex
cochaperon
result
except
select
complex
compar
free
intrigu
possibl
suggest
either
multichaperonebound
compon
multichaperon
figur
model
tumor
select
inhibitor
malign
progress
normal
cell
exist
uncomplex
form
lowaffin
inhibitor
drug
accumul
poorli
normal
tissu
normal
cell
exhibit
poor
drug
sensit
contrast
cancer
cell
involv
activ
chaperon
overexpress
oncoprotein
exist
complex
form
cochaperon
protein
hop
complex
complex
cancer
cell
exhibit
highaffin
bind
inhibitor
drug
accumul
tumor
tissu
tumor
cell
exhibit
good
drug
sensit
model
predict
accumul
mutant
protein
advanc
cancer
would
increas
usag
make
tumor
cell
depend
furthermor
model
suggest
highaffin
chang
driven
overexpress
oncoprotein
well
stress
condit
normal
cell
eg
heat
complex
respons
catalyz
conform
chang
geldanamycin
enabl
bind
highaffin
altern
complex
cochaperon
protein
might
caus
conform
chang
nucleotid
bind
pocket
geldanamycin
deriv
bind
higher
affin
recent
crystal
structur
anoth
geldanamycin
deriv
human
solv
molecular
model
studi
suggest
constrain
cisamid
bond
ground
state
would
increas
bind
affin
latter
chang
might
occur
easili
complex
cochaperon
protein
thu
modul
higher
bind
affin
complex
cochaperon
protein
hop
found
modul
activ
increas
bind
affin
atpas
activ
set
cochaperon
previous
use
vitro
reconstitut
experi
need
activ
progesteron
receptor
previou
data
show
hop
strongli
inhibit
weakli
inhibit
atpas
experi
perform
use
yeast
contrast
human
much
weaker
atpas
yeast
hop
littl
effect
basal
atpas
rate
inhibit
clientproteinstimul
atpas
rate
wherea
exhibit
small
suppress
result
suggest
format
multichaperon
complex
dynam
process
regul
activ
interest
determin
effect
two
cochaperon
protein
affin
inhibitor
import
chaperon
kinas
increas
atpas
activ
unlik
cochaperon
bind
cterminu
crystal
structur
reveal
bind
nterminu
prevent
transactiv
interact
ntermin
domain
thu
inhibit
atpas
activ
central
region
involv
direct
interact
suggest
increas
atpas
activ
stabil
interact
central
ntermin
domain
therefor
futur
studi
aim
better
understand
dynam
role
cochaperon
protein
modul
activ
increas
bind
affin
inhibitor
diagnost
applic
assay
profound
differ
activ
normal
malign
cell
reveal
use
three
experiment
approach
competitivebind
assay
use
extract
cell
lysat
coimmunoprecipit
cochaperon
protein
atpas
activ
magnitud
diverg
term
bind
affin
percentag
free
versu
complex
close
correl
bind
affin
cellkil
potenc
r
suggest
analys
could
signific
diagnost
valu
lysatebind
assay
perform
quantiti
malign
tissu
could
obtain
routin
blood
sampl
leukemia
fineneedl
aspir
tumor
rais
hope
current
method
streamlin
version
could
use
guid
patient
select
clinic
develop
inhibitor
type
assay
could
advantag
exist
molecular
diagnost
herceptest
addit
measur
level
sampl
indic
extent
tumor
use
depend
upon
clearli
simpler
methodolog
immunoassay
determin
usag
clinic
sampl
would
prefer
antibodi
recogn
uncomplex
might
use
tool
measur
decreas
usag
better
reagent
would
antibodi
specif
recogn
highaffin
conform
antibodi
might
recogn
epitop
produc
close
juxtaposit
cochaperon
protein
activ
conformationspecif
epitop
conformationspecif
antibodi
report
endoplasm
reticulum
homolog
remain
seen
conformationspecif
antibodi
develop
inhibitor
might
therapeut
potenti
condit
diseas
cell
depend
increas
activ
cellular
recruit
cell
undergo
viral
infect
mediat
autoimmun
respons
inhibit
might
use
treat
diseas
furthermor
inhibitor
also
upregul
heatshock
protein
provid
protect
function
central
nervou
system
cn
disord
cardiovascular
diseas
possibl
increas
usag
diseas
could
provid
select
therapeut
target
highaffin
bind
inhibitor
within
diseas
tissu
case
unlik
cellular
chang
diseas
cell
profound
highli
malign
cell
interest
determin
whether
activ
might
repres
use
independ
diagnost
andor
prognost
marker
nononcolog
diseas
viral
infect
stress
infect
cell
reflect
increas
express
heatshock
protein
includ
viru
essenti
steal
host
facilit
assembl
replic
studi
demonstr
geldanamycin
block
viral
lifecycl
hepat
b
viru
hbv
hepat
c
viru
hcv
herp
simplex
viru
type
essenti
host
factor
hbv
replic
interact
viral
revers
transcriptas
also
necessari
activ
proteas
hcv
furthermor
recent
studi
show
replic
vitro
significantli
inhibit
geldanamcyin
ic
nm
wherea
geldanamycin
inhibit
cellular
growth
uninfect
cell
ic
mm
suggest
good
therapeut
select
studi
also
demonstr
geldanamycin
exhibit
broadspectrum
activ
rang
virus
ic
mm
sar
coronaviru
exhibit
highest
sensit
mechan
inhibit
might
explain
abil
geldanamycin
block
tat
activ
effect
host
cofactor
therefor
studi
suggest
inhibitor
could
use
multipl
viral
diseas
remain
determin
whether
viral
infect
cell
exhibit
highaffin
bind
inhibitor
could
provid
therapeut
select
viral
infect
uninfect
cell
autoimmun
diseas
result
inappropri
persist
lymphocyt
activ
aberr
respons
self
determin
destruct
symptom
autoimmun
might
aris
action
cell
bcellderiv
antibodi
complement
fixat
b
lymphocyt
use
similar
signal
transduct
pathway
mitogen
activ
program
tumor
cell
suggest
modul
might
potent
inhibitor
lymphocyt
function
yorgin
et
al
show
connect
inhibit
tcell
activ
kill
activ
cell
geldanamycin
degrad
nonreceptor
tyrosin
kinas
lck
geldanamycin
also
deplet
inhibitorsensit
client
rat
splenocyt
consequ
block
rat
tcell
prolifer
respons
repeat
exposur
antigen
furthermor
inhibitor
also
block
raferkmedi
prolifer
murin
b
cell
stimul
bcell
antigen
receptor
taken
togeth
studi
suggest
antibodymedi
autoimmun
diseas
could
doubli
affect
inhibit
tcell
bcell
compart
ischemia
stress
phenomenon
accompani
cerebrovascular
cardiovascular
diseas
state
heatshock
protein
upregul
stress
respons
provid
neuroprotect
cardioprotect
ischem
damag
geldanamycin
via
pathway
also
caus
upregul
heatshock
protein
includ
protect
role
stressinduc
ischem
damag
exert
potent
antiapoptot
activ
inhibit
assembl
caspas
c
apoptosom
studi
demonstr
geldanamycin
effect
posttreat
neuroprotect
agent
cellcultur
model
oxid
toxic
also
protect
brain
focal
ischemia
vivo
rat
model
provid
strong
evid
inhibitor
could
use
neuroprotect
agent
geldanamycin
also
shown
induc
heatshock
respons
myogen
cell
confer
protect
ischem
stress
suggest
inhibitor
offer
pharmacolog
method
increas
level
heatshock
protein
cardiac
tissu
thu
protect
heart
ischem
injuri
addit
ischem
injuri
evid
inhibitor
could
util
proteinaggreg
diseas
cn
huntington
diseas
hd
nanomolar
concentr
geldanamycin
activ
heatshock
respons
inhibit
hd
protein
aggreg
cellcultur
model
hd
furthermor
asynucleinmut
fli
fed
drug
complet
protect
neuron
loss
drosophila
model
parkinson
diseas
collect
studi
suggest
inhibitor
could
use
modul
heatshock
respons
provid
protect
function
damag
cell
brain
heart
inhibit
protein
regul
multipl
signal
transduct
pathway
cancer
cell
attract
approach
cancer
therapi
involv
conform
matur
variou
oncogen
signal
protein
emerg
prime
target
anticanc
drug
depend
cancer
cell
activ
form
suggest
multichaperon
complex
could
uniqu
cancer
target
provid
mechan
inhibitor
select
destroy
cancer
cell
normal
cell
might
serv
analog
role
somat
evolut
tumor
darwinian
evolut
rescu
potenti
misfold
mutant
protein
prevent
mutat
becom
lethal
cell
thu
enabl
oncoprotein
support
tumorcel
prolifer
surviv
malign
work
requir
determin
close
usag
mirror
diseas
progress
cancer
condit
increas
usag
cancer
cell
might
use
diagnost
tool
stratifi
patient
clinic
trial
inhibitor
independ
stage
criterion
rang
diseas
